News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Daiichi Sankyo Co Ltd. Upbeat on Drug to Prevent Strokes and Clots
February 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Feb 21 (Reuters) - Japan's Daiichi Sankyo Co Ltd said on Thursday it was highly satisfied with mid-stage results for a key drug to prevent strokes and clots, and would move on to late-stage trials despite fierce competition in the field.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Asia
Europe
Daiichi Sankyo
MORE ON THIS TOPIC
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
China
Trump Reportedly Preparing Order Restricting Chinese Drug Licensing Deals
September 11, 2025
·
2 min read
·
Dan Samorodnitsky
Gene therapy
Capsida Reports Patient Death in Gene Therapy Trial
September 11, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
September 11, 2025
·
2 min read
·
Tristan Manalac
